Novartis wins FDA nod for Afinitor in advanced breast cancer
This article was originally published in Scrip
Executive Summary
The US FDA late on 20 July gave its blessing to Novartis to market its kinase inhibitor Afinitor (everolimus) in combination with Pfizer's Aromasin (exemestane) as a treatment for certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer following therapy with Femara (letrozole) or Arimidex (anastrozole), marketed by Novartis and AstraZeneca, respectively.